FATE 241018 3.00C (FATE241018C3000) Stock Options, News & Quotes

US OptionsDetailed Quotes

FATE241018C3000

Watchlist

0.19
-0.06-24.00%

15min DelayClose Oct 18 16:00 ET

0.25High0.19Low

Intraday

5D
Daily

News

Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswireOct 2 16:01 ET
Fate Therapeutics to Present at 2024 Cantor Global Healthcare Conference
GlobeNewswireSep 12 16:01 ET
Fate Therapeutics Strengthens Legal Safeguards for Leadership
TipRanksAug 30 16:49 ET
H.C. Wainwright Maintains Fate Therapeutics(FATE.US) With Hold Rating, Maintains Target Price $5
Moomoo NewsAug 22 06:31 ET · Ratings
Analysts Offer Insights on Healthcare Companies: PROCEPT BioRobotics (PRCT) and Fate Therapeutics (FATE)
TipRanksAug 22 06:20 ET · Ratings
Fate Therapeutics: Hold Rating Amid Financial Stability and Upcoming Milestones
TipRanksAug 22 06:20 ET · Ratings

Comments

Tonyco

Sep 30 13:39

$Metagenomi Technologies, LLC (MGX.US)$ $Lantronix (LTRX.US)$
$Fate Therapeutics (FATE.US)$
$Navitas Semiconductor (NVTS.US)$
Opened up some positions on these today.
Increased $Rivian Automotive (RIVN.US)$ , $X4 Pharmaceuticals (XFOR.US)$
Took profit on $FTC Solar (FTCI.US)$ , $GigaCloud Technology (GCT.US)$ and $Aurora Innovation (AUR.US)$
I'll be back in GCT and AUR for sure.
Still looking at $Spero Therapeutics (SPRO.US)$ and $Acacia Research (ACTG.US)$ too.
Exciting day for dips!

Jaguar8

May 29 15:04

NEWS

$Fate Therapeutics (FATE.US)$
Fate Therapeutics to Present at 2024 Jefferies Global Healthcare Conference
Fate Therapeutics, a clinical-stage biopharmaceutical company focusing on iPSC-derived cellular immunotherapies for cancer and autoimmune diseases, announced their participation in the 2024 Jefferies Global Healthcare Conference. The presentation is scheduled for June 5, 2024, at 3:00 PM ET in New York. The event will be webcasted live and accessible on the Company’s website, with an arch...

Trytosaveabit

May 9 07:35

Update

$Fate Therapeutics (FATE.US)$ Fate Therapeutics Treats First Lupus Patient In Phase 1 Study Of FT819 CAR T-Cell Therapy

Jaguar8

May 9 07:33

$Fate Therapeutics (FATE.US)$
NEWS
Fate Therapeutics Announces First Lupus Patient Treated in Phase 1 Autoimmunity Study of Off-the-shelf FT819 CAR T-cell Program

Meltyy

Apr 2 22:13

Gear up for AACR24!

See Biotech companies with cancer assets 👇
⇨ held by 5 biopharma-focused hedge funds! 🔥
$Arcellx (ACLX.US)$ : Anito-cel (Ph 2)
$Adaptimmune Therapeutics (ADAP.US)$ : Afami-cel (PDUFA) ⏳
$Bicycle Therapeutics (BCYC.US)$ : BT8009 (Ph 1/2)
$Centessa Pharmaceuticals (CNTA.US)$ : LB101 (Ph 1/2)
$Day One Biopharmaceuticals (DAWN.US)$ : Tovorafenib (PDUFA) (check comments for details)
$Fate Therapeutics (FATE.US)$ : FT576 (Ph 1)
$Fusion Pharmaceuticals (FUSN.US)$ : FPI-2265 (Ph 2)
$GRCL: ...